Supporting Healthcare Professionals
The Knight Diagnostic Laboratories provide a broad menu of tests that are designed to yield the maximum amount of actionable information for the least cost. As members of the Knight Cancer Institute, the laboratory directors work closely with OHSU oncologists, hematologists, geneticists and infectious disease specialists to get expert input on which new tests will provide the most cost-effective impact on clinical care.
Answers to common questions about the Knight Diagnostic Laboratories:
What type of specimen is required?
All cancer genotyping assays developed in the Knight Diagnostic Laboratories can be performed on formalin-fixed, paraffin-embedded (FFPE) tissues, but will also work on fresh frozen tissue, as well as DNA prepared from blood or bone marrow. In addition, cytogenetic FISH assays can be performed on FFPE tissue sections. Genetic assays are generally performed on DNA from peripheral blood. Specimen requirements are detailed in the Test Information Sheet for each test offered by the Laboratories.
Will insurance cover the cost of tests offered by the Knight Diagnostic Labs? What about Medicare?
The Laboratories work with all major insurance companies including Medicare. In addition, the Labs will seek pre-authorization for complex tests that may not automatically be covered by an insurer.
How much will my patient have to pay?
Out-of-pocket costs for a patient will depend on his/her insurance plan, yearly deductible, and standard co-pay. Estimates can be provided on request.
Is genetic counseling available?
Genetic counselors from Oregon Health & Science University are available for consultation upon request.
Dr. Christopher Corless, Dr. Carol Beadling, Dr. Yassmine Akkari and other members of the of the Knight Diagnostic Laboratories, contributed to two posters presented at AMP
by
User Not Found | Dec 12, 2014
As part of the NHGRI CSER Consortium, The Knight Diagnostic Laboratories collaborated on the classification and Sanger confirmation of variants detected ...
As part of the NHGRI CSER Consortium, The Knight Diagnostic Laboratories collaborated on the classification and Sanger confirmation of variants detected through carrier screening of healthy women presenting for preconception genetic testing using Whole Genome Sequencing (WGS).
In a poster presented at AMP, Dr. Yassmine Akkari describes our findings in the first four patients and discuss potential issues that arise when screening a population of healthy individuals.
Dr. Christopher Corless, Dr. Carol Beadling and other members of the of the Knight Diagnostic Laboratories, contributed to two posters. One discussed Amplification-Based Next-Gen Sequencing Panel For the Detection of Actionable Gene Fusions in Cancer and the second discussed the Impact of Next-Generation DNA Sequencing in GI Malignancies.